COLLEGIUM PHARMACEUTICAL, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.51 USD | 0.00% |
|
+2.99% | +21.86% |
| 04-29 | Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER | CI |
| 04-11 | Collegium Pharmaceutical to Redeem $26.35 Million of Senior Notes | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 690 | 692.7 | 650 | 778.9 | 1,004 | 1,227 | - | - |
| Enterprise Value (EV) 1 | 531.5 | 775.7 | 650 | 778.9 | 1,004 | 1,227 | 1,227 | 1,227 |
| P/E ratio | -30.3 x | 26.4 x | 10 x | -31.4 x | 23.9 x | 12.7 x | 10.1 x | 8.45 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.33 x | 2.23 x | 2.35 x | 1.68 x | 1.77 x | 2.11 x | 2.06 x | 2.18 x |
| EV / Revenue | 2.33 x | 2.23 x | 2.35 x | 1.68 x | 1.77 x | 2.11 x | 2.06 x | 2.18 x |
| EV / EBITDA | 91.6 x | 4.96 x | 5.49 x | 2.93 x | 2.74 x | 3.2 x | 3.14 x | 3.42 x |
| EV / FCF | 32.3 x | - | - | - | 3.66 x | 4.21 x | 3.94 x | - |
| FCF Yield | 3.09% | - | - | - | 27.3% | 23.8% | 25.4% | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 33,527 | 34,582 | 34,797 | 33,572 | 32,611 | 32,706 | - | - |
| Reference price 2 | 20.58 | 20.03 | 18.68 | 23.20 | 30.78 | 37.51 | 37.51 | 37.51 |
| Announcement Date | 20-02-27 | 21-02-25 | 22-02-24 | 23-02-23 | 24-02-22 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 296.7 | 310 | 276.9 | 463.9 | 566.8 | 581.7 | 594.6 | 561.9 |
| EBITDA 1 | 7.532 | 139.7 | 118.3 | 266 | 367 | 383.9 | 390.8 | 358.4 |
| EBIT 1 | -23.75 | 56.23 | 17.63 | 33.32 | 167 | 212.9 | 226.9 | 232 |
| Operating Margin | -8% | 18.14% | 6.37% | 7.18% | 29.46% | 36.59% | 38.16% | 41.29% |
| Earnings before Tax (EBT) 1 | -22.72 | 27.58 | -3.374 | -28.85 | 75.73 | 167.6 | 201.9 | 233.8 |
| Net income 1 | -22.72 | 26.75 | 71.52 | -25 | 48.16 | 115.6 | 145 | 174.3 |
| Net margin | -7.66% | 8.63% | 25.83% | -5.39% | 8.5% | 19.87% | 24.38% | 31.03% |
| EPS 2 | -0.6800 | 0.7600 | 1.860 | -0.7400 | 1.290 | 2.942 | 3.705 | 4.440 |
| Free Cash Flow 1 | 21.34 | - | - | - | 274.3 | 291.6 | 311.2 | - |
| FCF margin | 7.19% | - | - | - | 48.4% | 50.12% | 52.34% | - |
| FCF Conversion (EBITDA) | 283.39% | - | - | - | 74.74% | 75.95% | 79.64% | - |
| FCF Conversion (Net income) | - | - | - | - | 569.59% | 252.29% | 214.69% | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 20-02-27 | 21-02-25 | 22-02-24 | 23-02-23 | 24-02-22 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 78.84 | 27.36 | 83.75 | 123.5 | 127 | 129.6 | 144.8 | 135.5 | 136.7 | 149.7 | 146.9 | 141.9 | 143.5 | 149.4 | 150.7 |
| EBITDA 1 | 37.34 | -4.478 | 43.53 | 71.18 | 74.87 | 76.44 | 87.62 | 85.81 | 89.39 | 104.2 | 93.77 | 92.23 | 95.14 | 102.1 | 95.52 |
| EBIT 1 | 14.15 | -34.12 | -10.02 | 11.11 | 20.47 | 11.76 | 24.63 | 35.63 | 45.01 | 61.69 | 53.65 | 49.56 | 51.98 | 57.7 | 51.22 |
| Operating Margin | 17.95% | -124.71% | -11.96% | 8.99% | 16.11% | 9.07% | 17.01% | 26.29% | 32.93% | 41.2% | 36.51% | 34.92% | 36.23% | 38.61% | 34% |
| Earnings before Tax (EBT) 1 | 9.037 | -38.88 | -15.84 | -6.646 | 1.432 | -7.791 | -17.56 | 17.8 | 28.78 | 46.71 | 40.11 | 37.54 | 41.38 | 48.56 | 43.35 |
| Net income 1 | 8.046 | -25.03 | -13.07 | -5.191 | 0.457 | -7.199 | -17.43 | 13.01 | 20.63 | 31.94 | 25.12 | 24.57 | 29.31 | 36.56 | 31.21 |
| Net margin | 10.21% | -91.49% | -15.6% | -4.2% | 0.36% | -5.55% | -12.04% | 9.6% | 15.09% | 21.33% | 17.1% | 17.32% | 20.43% | 24.47% | 20.72% |
| EPS 2 | 0.2200 | -0.7300 | -0.3900 | -0.1500 | 0.0100 | -0.2200 | -0.5100 | 0.3400 | 0.6100 | 0.8200 | 0.6350 | 0.6225 | 0.7550 | 0.9375 | 0.8400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 21-11-04 | 22-02-24 | 22-05-10 | 22-08-04 | 22-11-03 | 23-02-23 | 23-05-04 | 23-08-03 | 23-11-07 | 24-02-22 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | 83 | - | - | - | - | - | - |
| Net Cash position | 159 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 0.594 x | - | - | - | - | - | - |
| Free Cash Flow 1 | 21.3 | - | - | - | 274 | 292 | 311 | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 6.44 | 5.55 | 1.94 | 1.62 | 0.46 | 0.7 | 0.7 | 1 |
| Capex / Sales | 2.17% | 1.79% | 0.7% | 0.35% | 0.08% | 0.12% | 0.12% | 0.18% |
| Announcement Date | 20-02-27 | 21-02-25 | 22-02-24 | 23-02-23 | 24-02-22 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
37.51
USD
Average target price
40
USD
Spread / Average Target
+6.64%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +21.86% | 1.23B | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B | |
| -3.40% | 157B |
- Stock Market
- Equities
- COLL Stock
- Financials Collegium Pharmaceutical, Inc.
